
    
      Up to 2-week screening period

        -  A run-in period of 12 weeks at maximum including a forced titration with insulin
           glargine up to 11 weeks and 1 baseline pharmacodynamic assessment week

        -  A 8-week treatment(s) period(s) up to Day 57

        -  Follow-up: 7 Â±2 days after the last treatment day

        -  Total study duration approximately 14 weeks up to 23 weeks
    
  